Paper2491964
Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin.
Balazsovits JA and 6 others. Cancer Chemother Pharmacol, 1989. Cited by 100 papers, by iCite.
Cite this record
ConductScience Library. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Papers, record 2491964. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2491964
- Disease
- breast cancer1,032 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin.
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Doxorubicin | Major topic |
| Heart | Major topic |
| Liposomes | Major topic |
| Animals | |
| DNA | |
| Edema | |
| Female | |
| Hydrogen-Ion Concentration | |
| Irritants | |
| Mast-Cell Sarcoma | |
| Mice | |
| Mice, Inbred DBA |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01367028 | A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer | Results |
Source ClinicalTrials.gov
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7127308 | Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. | Cancer Res | 1982 | https://conductscience.org/library/papers/7127308 | PubMed |
| 2 | 4005257 | Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. | Biochim Biophys Acta | 1985 | https://conductscience.org/library/papers/4005257 | PubMed |
| 3 | 3964703 | Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. | Biochim Biophys Acta | 1986 | https://conductscience.org/library/papers/3964703 | PubMed |
| 4 | 3967247 | Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. | Cancer Res | 1985 | https://conductscience.org/library/papers/3967247 | PubMed |
| 5 | 6883331 | Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. | Cancer Res | 1983 | https://conductscience.org/library/papers/6883331 | PubMed |
| 6 | 7370991 | Liposomal protection of adriamycin-induced cardiotoxicity in mice. | Cancer Res | 1980 | https://conductscience.org/library/papers/7370991 | PubMed |
| 7 | 3941333 | Doxorubicin-induced skin necrosis in the swine model: protection with a novel radical dimer. | J Clin Oncol | 1986 | https://conductscience.org/library/papers/3941333 | PubMed |
| 8 | 7034780 | Liposome disposition in vivo. III. Dose and vesicle-size effects. | Biochim Biophys Acta | 1981 | https://conductscience.org/library/papers/7034780 | PubMed |
| 9 | 23008845 | Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. | Biochim Biophys Acta | 1985 | https://conductscience.org/library/papers/23008845 | PubMed |
| 10 | 6848178 | Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. | Cancer Res | 1983 | https://conductscience.org/library/papers/6848178 | PubMed |
| 11 | 3742676 | Techniques for encapsulating bioactive agents into liposomes. | Chem Phys Lipids | 1986 | https://conductscience.org/library/papers/3742676 | PubMed |
| 12 | 6850663 | Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. | Cancer Treat Rep | 1983 | https://conductscience.org/library/papers/6850663 | PubMed |
| 13 | 7057359 | Liposome disposition in vivo II: Dose dependency. | J Pharm Sci | 1982 | https://conductscience.org/library/papers/7057359 | PubMed |
| 14 | 6459710 | Tissue distribution and antitumor effect of liposome-entrapped doxorubicin (adriamycin) in Ehrlich solid tumor-bearing mouse. | Acta Med Okayama | 1981 | https://conductscience.org/library/papers/6459710 | PubMed |
| 15 | 6897042 | Is half-life of circulating liposomes determined by changes in their permeability? | FEBS Lett | 1982 | https://conductscience.org/library/papers/6897042 | PubMed |
| 16 | 7201392 | Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. | Eur J Cancer Clin Oncol | 1982 | https://conductscience.org/library/papers/7201392 | PubMed |
Cited by35
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 100 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39861690 | Liposomal Formulation of Hydroxychloroquine Can Inhibit Autophagy In Vivo. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39861690 | PubMed |
| 36572154 | Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy. | J Control Release | 2023 | https://conductscience.org/library/papers/36572154 | PubMed |
| 36015347 | Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36015347 | PubMed |
| 35957103 | Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy. | Nanomaterials (Basel) | 2022 | https://conductscience.org/library/papers/35957103 | PubMed |
| 35057002 | Development of Pharmaceutical Nanomedicines: From the Bench to the Market. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35057002 | PubMed |
| 33921088 | Monomethyl Auristatin E Grafted-Liposomes to Target Prostate Tumor Cell Lines. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33921088 | PubMed |
| 33449342 | Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities. | Drug Deliv Transl Res | 2021 | https://conductscience.org/library/papers/33449342 | PubMed |
| 31209826 | Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin. | Drug Deliv Transl Res | 2019 | https://conductscience.org/library/papers/31209826 | PubMed |
| 31161432 | Fibrin Gels Entrapment of a Poly-Cyclodextrin Nanocarrier as a Doxorubicin Delivery System in an Orthotopic Model of Neuroblastoma: Evaluation of In Vitro Activity and In Vivo Toxicity. | Pharm Res | 2019 | https://conductscience.org/library/papers/31161432 | PubMed |
| 30884782 | What Drives Innovation: The Canadian Touch on Liposomal Therapeutics. | Pharmaceutics | 2019 | https://conductscience.org/library/papers/30884782 | PubMed |
| 29459867 | The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases. | Front Immunol | 2018 | https://conductscience.org/library/papers/29459867 | PubMed |
| 29353083 | Combining ultrasound and intratumoral administration of doxorubicin-loaded microspheres to enhance tumor cell killing. | Int J Pharm | 2018 | https://conductscience.org/library/papers/29353083 | PubMed |
| 28839175 | Oxygen nanobubbles revert hypoxia by methylation programming. | Sci Rep | 2017 | https://conductscience.org/library/papers/28839175 | PubMed |
| 28346375 | Liposomal Formulations in Clinical Use: An Updated Review. | Pharmaceutics | 2017 | https://conductscience.org/library/papers/28346375 | PubMed |
| 27155765 | Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines. | J Pharm Sci | 2016 | https://conductscience.org/library/papers/27155765 | PubMed |
| 25514405 | Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages. | Int J Mol Sci | 2014 | https://conductscience.org/library/papers/25514405 | PubMed |
| 25316273 | Multistage Nanovectors Enhance the Delivery of Free and Encapsulated Drugs. | Curr Drug Targets | 2015 | https://conductscience.org/library/papers/25316273 | PubMed |
| 23210520 | Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. | Exp Hematol Oncol | 2012 | https://conductscience.org/library/papers/23210520 | PubMed |
| 18203425 | Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. | Int J Nanomedicine | 2007 | https://conductscience.org/library/papers/18203425 | PubMed |
| 11523222 | Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer. | J Tongji Med Univ | 2001 | https://conductscience.org/library/papers/11523222 | PubMed |
Drugs4
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| BEVACIZUMAB | CHEMBL1201583 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1201583 | ChEMBL |
| TRASTUZUMAB | CHEMBL1201585 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1201585 | ChEMBL |
| DOCETAXEL | CHEMBL3545252 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL3545252 | ChEMBL |
| DOXORUBICIN | CHEMBL53463 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL53463 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2491964
GET https://conductscience.org/api/papers/v1/2491964/cited_by?page=2